Drugs / Puxitatug Samrotecan
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05123482 | Oct 2021 → Sep 2027 expected | biliary tract cancer, breast carcinoma, endometrial cancer, non-small cell squamous lung carcinoma +1 | AstraZeneca | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07162480 | Apr 2026 → Dec 2029 expected | adenoid cystic carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07044336 | Aug 2025 → Oct 2027 expected | endometrial cancer | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | puxitatug samrotecan | “Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)” NCT07162480 ↗2“AZD8205, puxitatug samrotecan, a B7-H4-directed cysteine-conjugated ADC bearing a novel topoisomerase I inhibitor payload” PMID 39392424 ↗ Oct 2024 |
| Known as | AZD8205 | “Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)” NCT07162480 ↗2“Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)” NCT07044336 ↗ |
| Modality | Other / unclassified | “AZD8205 is an antibody drug conjugate” NCT05123482 ↗ |
| Route | Intravenous | “Route of administration: IV infusion” NCT07044336 ↗ |